Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.

Brain tumor pathology - 1 Jan 2022

Nishikawa Tomohide, Watanabe Reiko, Kitano Yotaro, Yamamichi Akane, Motomura Kazuya, Ohka Fumiharu, Aoki Kosuke, Hirano Masaki, Kato Akira, Yamaguchi Junya, Maeda Sachi, Kibe Yuji, Saito Ryuta, Wakabayashi Toshihiko, Kato Yukinari, Sato Shuta, Ogino Tomoyoshi, Natsume Atsushi, Ito Ichiro

Abstract excerpt

Since the World Health Organization 2016 classification (2016 WHO), genetic status has been incorporated into the diagnosis of Grade 2/3 gliomas (lower-grade gliomas). Therefore, immunohistochemistry (IHC) of IDH1-R132H, ATRX, and p53 have been used in place of genetic status. We report the associations between histological findings, IHC, and genetic status. We performed IHC of IDH1-R132H, ATRX, and p53 in 76...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Reproducibility of Results

Share to Tumor Suppressor Protein p53

Share to X-linked Nuclear Protein

Source

Identifiers

PMID: 34826036
DOI: 10.1007/s10014-021-00418-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.PMID 34826036Read ↗

Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases.Semantic proximity Read ↗

Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?Semantic proximity Read ↗

Expression Profiling of IDH, p53, ATRX, and KI-67 Immunostains as Potential Grid for Molecular Subtyping of Adult Diffuse Gliomas from PakistanSemantic proximity Read ↗

Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics.Semantic proximity Read ↗

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.Semantic proximity Read ↗

Study of Molecular Markers in Glioma and Their Association with Clinicopathological Features.Semantic proximity Read ↗

Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.Semantic proximity Read ↗

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).Semantic proximity Read ↗

Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system.Semantic proximity Read ↗

cIMPACT ‐ NOW update 11: Proposal on adaptation of diagnostic criteria for IDH ‐ and H3 ‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumorsSemantic proximity Read ↗

World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.Semantic proximity Read ↗

IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.